Climb Bio, Inc. (CLYM)

Climb Bio Statistics

Total Valuation

Climb Bio has a market cap or net worth of $180.00 million. The enterprise value is $4.75 million.

Market Cap	180.00M
Enterprise Value	4.75M

Important Dates

The last earnings date was Thursday, November 6, 2025, before market open.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Climb Bio has 47.74 million shares outstanding. The number of shares has increased by 76.96% in one year.

Current Share Class	47.74M
Shares Outstanding	47.74M
Shares Change (YoY)	+76.96%
Shares Change (QoQ)	+0.62%
Owned by Insiders (%)	1.79%
Owned by Institutions (%)	27.74%
Float	30.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.45
P/TBV Ratio	1.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 18.38, with a Debt / Equity ratio of 0.00.

Current Ratio	18.38
Quick Ratio	17.56
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -25.65% and return on invested capital (ROIC) is -17.70%.

Return on Equity (ROE)	-25.65%
Return on Assets (ROA)	-17.35%
Return on Invested Capital (ROIC)	-17.70%
Return on Capital Employed (ROCE)	-31.65%
Revenue Per Employee	n/a
Profits Per Employee	-$2.82M
Employee Count	18
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +101.60% in the last 52 weeks. The beta is -0.15, so Climb Bio's price volatility has been lower than the market average.

Beta (5Y)	-0.15
52-Week Price Change	+101.60%
50-Day Moving Average	2.95
200-Day Moving Average	1.96
Relative Strength Index (RSI)	49.50
Average Volume (20 Days)	1,055,959

Short Selling Information

The latest short interest is 1.82 million, so 3.81% of the outstanding shares have been sold short.

Short Interest	1.82M
Short Previous Month	2.22M
Short % of Shares Out	3.81%
Short % of Float	5.98%
Short Ratio (days to cover)	0.75

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-56.14M
Pretax Income	-50.75M
Net Income	-50.75M
EBITDA	n/a
EBIT	-56.14M
Earnings Per Share (EPS)	-$0.75

Balance Sheet

The company has $86.90 million in cash and $580,000 in debt, with a net cash position of $175.25 million or $3.67 per share.

Cash & Cash Equivalents	86.90M
Total Debt	580,000
Net Cash	175.25M
Net Cash Per Share	$3.67
Equity (Book Value)	177.00M
Book Value Per Share	2.60
Working Capital	86.02M

Cash Flow

In the last 12 months, operating cash flow was -$44.24 million and capital expenditures -$186,000, giving a free cash flow of -$44.43 million.

Operating Cash Flow	-44.24M
Capital Expenditures	-186,000
Free Cash Flow	-44.43M
FCF Per Share	-$0.93

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Climb Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-76.96%
Shareholder Yield	-76.96%
Earnings Yield	-28.20%
FCF Yield	-24.68%

Analyst Forecast

The average price target for Climb Bio is $9.50, which is 151.99% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.50
Price Target Difference	151.99%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1